How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about lenalidomide

Marketing authorisation indication

2.1 Lenalidomide (Revlimid, Celgene) is indicated for 'the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price for lenalidomide is £3,780 per pack of 21 tablets, each containing 10 mg of the active ingredient (excluding VAT; BNF online, August 2020). The company has a commercial arrangement. This makes lenalidomide available to the NHS with a discount, which would have applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.